PepGen Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $18.0 million, a decrease from a net loss of $21.4 million in the same period last year. The company’s total operating expenses for the quarter were $18.7 million, down from $23.2 million in the prior year, primarily due to reduced research and development costs. Research and development expenses decreased to $13.4 million from $17.7 million, reflecting a decline in personnel-related costs and manufacturing expenses as the company advanced its clinical programs.
In terms of financial position, PepGen's total assets increased to $190.1 million as of September 30, 2025, compared to $150.9 million at the end of 2024. This growth was driven by a significant increase in cash and cash equivalents, which rose to $142.8 million from $49.4 million, following a successful public offering that generated net proceeds of $107.6 million. The company’s accumulated deficit also widened to $342.8 million, up from $271.5 million at the end of 2024, as it continues to invest heavily in its clinical development programs.
Strategically, PepGen has made notable adjustments to its product pipeline. The company announced the voluntary discontinuation of its PGN-EDO51 program for Duchenne muscular dystrophy (DMD) in May 2025, reallocating resources to its lead candidate, PGN-EDODM1, which is currently in Phase 2 clinical trials. The ongoing FREEDOM study has shown promising results, with a reported mean splicing correction of 53.7% following a single dose of PGN-EDODM1, and the company plans to expand the trial to additional geographies, including the U.S.
Operationally, PepGen's workforce has grown, reflecting its commitment to advancing its clinical programs. The company is focused on enhancing its research and development capabilities while managing costs effectively. As of September 30, 2025, PepGen had cash, cash equivalents, and marketable securities totaling $163.7 million, which it believes will be sufficient to fund operations into the second half of 2027. However, the company acknowledges the need for additional funding to support ongoing and future development activities, emphasizing the importance of securing capital through equity offerings or strategic partnerships.
Looking ahead, PepGen remains focused on the clinical advancement of PGN-EDODM1 and is optimistic about its potential to address severe neuromuscular diseases. The company is also exploring additional investigational drugs targeting other conditions, although it recognizes the inherent risks and uncertainties associated with drug development. The management's outlook reflects a cautious optimism, balancing the need for continued investment in research and development with the realities of funding and market conditions.
About PepGen Inc.
PepGen Inc. is a biotechnology company developing oligonucleotide therapeutics using its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. Focused on neuromuscular and neurological diseases like Duchenne muscular dystrophy and myotonic dystrophy, it leverages cell-penetrating peptides to improve tissue delivery and efficacy. Its pipeline includes clinical-stage exon-skipping and splicing correction programs, aiming to address genetic root causes with enhanced safety, potency, and scalability.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.